A computational biologist's personal views on new technologies & publications on genomics & proteomics and their impact on drug discovery
Monday, June 12, 2023
Illumina: Where Was the Board?
Sunday brought news that Francis deSouza had resigned as CEO of Illumina. It at first might have seemed he had survived the boardroom challenge from activist investor Carl Icahn, losing only one ally - Board Chairman John Thompson. But that apparently effectively made him a lame duck, and he is now leaving immediately -- leaving no one at the helm of Illumina momentarily but also eliminating any interference from deSouza with the installation of his successor. If you have access to STAT+, Matt Herper's commentary is very informative (I'd expect nothing less).